secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K/A
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001193125-26-157038
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics files audited Faeth financials; net loss $16M in 2025, going-concern doubt
--------------------------------------------------------------------------------

- Faeth net loss $16.0M in 2025 ($18.3M in 2024); accumulated deficit $77.7M at Dec 31, 2025.
- R&D expenses $12.0M (2025) vs $14.1M (2024); cash & equivalents $20.4M at Dec 31, 2025.
- Auditor cites substantial doubt about going concern due to potential cash payments from $200M PIPE Series B preferred.
- Acquisition of Faeth closed Feb 17, 2026; concurrent $200M PIPE closed Feb 20, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526157038/0001193125-26-157038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526157038/d40329d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-157038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer